Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.
Standard
Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany. / Hoffmann, Falk; Bussche van den, Hendrik; Glaeske, Gerd; Kaduszkiewicz, Hanna.
in: INT CLIN PSYCHOPHARM, Jahrgang 25, Nr. 1, 1, 2010, S. 29-36.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany.
AU - Hoffmann, Falk
AU - Bussche van den, Hendrik
AU - Glaeske, Gerd
AU - Kaduszkiewicz, Hanna
PY - 2010
Y1 - 2010
N2 - The objective of this study was to evaluate long-term trends of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine prescriptions in Germany according to sex, age and type of prescribing medical specialist. We used data of the statutory health insurance company Gmünder ErsatzKasse for persons aged 65 years and older over the years 2000-2007. Trends in prescription prevalences were stratified and directly standardized. The standardized prescription prevalence of antidementia drugs in persons aged > or =65 years doubled in the period of 8 years in males (from 0.66% in 2000 to 1.32% in 2007) and in females (from 0.88 to 1.73%). We found significant 2.12-2.48-fold increases for the age group 80 years and above, smaller in the age group 70-79 years (1.57-1.94-fold) and no clear trend for those in the age range 65-69 years. The proportion of memantine prescribed by neurologists and psychiatrists increased from 22.6% in 2000 to 45.8% in 2007. Our study gives first insights into prescribing trends of antidementia drugs in Germany. Further evidence from health services research on dementia care is clearly needed.
AB - The objective of this study was to evaluate long-term trends of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine prescriptions in Germany according to sex, age and type of prescribing medical specialist. We used data of the statutory health insurance company Gmünder ErsatzKasse for persons aged 65 years and older over the years 2000-2007. Trends in prescription prevalences were stratified and directly standardized. The standardized prescription prevalence of antidementia drugs in persons aged > or =65 years doubled in the period of 8 years in males (from 0.66% in 2000 to 1.32% in 2007) and in females (from 0.88 to 1.73%). We found significant 2.12-2.48-fold increases for the age group 80 years and above, smaller in the age group 70-79 years (1.57-1.94-fold) and no clear trend for those in the age range 65-69 years. The proportion of memantine prescribed by neurologists and psychiatrists increased from 22.6% in 2000 to 45.8% in 2007. Our study gives first insights into prescribing trends of antidementia drugs in Germany. Further evidence from health services research on dementia care is clearly needed.
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Aged, 80 and over
KW - Sex Factors
KW - Age Factors
KW - Cholinesterase Inhibitors therapeutic use
KW - Cognition Disorders drug therapy
KW - Dementia drug therapy
KW - Drug Utilization trends
KW - Memantine therapeutic use
KW - Physician's Practice Patterns trends
KW - Germany
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Aged, 80 and over
KW - Sex Factors
KW - Age Factors
KW - Cholinesterase Inhibitors therapeutic use
KW - Cognition Disorders drug therapy
KW - Dementia drug therapy
KW - Drug Utilization trends
KW - Memantine therapeutic use
KW - Physician's Practice Patterns trends
M3 - SCORING: Zeitschriftenaufsatz
VL - 25
SP - 29
EP - 36
JO - INT CLIN PSYCHOPHARM
JF - INT CLIN PSYCHOPHARM
SN - 0268-1315
IS - 1
M1 - 1
ER -
